ment of Her2/ neu -positive cancers with trastuzumab (herceptin)-containing treatment regimes [5, 6] , due to our poor understanding of the complex biology of breast cancer, the majority of patients receive some form of nonindividualized chemotherapy, but as few as 50% benefi t from this.
Drug Resistance in Breast Cancer
Cytotoxic drugs play an important role in the treatment of breast cancer [7] [8] [9] . However, chemotherapy resistance, whether inherent or acquired, is a major problem in the management of breast cancer. Patients refractory to chemotherapy often exhibit resistance to multiple cytotoxic agents, often of differing structures and differing functions. The basis for the multiple drug resistance (MDR) is likely to be multifactorial and heterogenous [8, 10, 11] , with many molecular mechanisms potentially contributing to the drug resistance phenotype.
Drug Effl ux Pumps
Several of the transmembrane drug effl ux pumps belong to the ATP-binding cassette (ABC) transmembrane protein superfamily that utilizes energy from ATP hydrolysis to translocate substrates across cell membranes [8, 12] . This mechanism of drug resistance may be clinically relevant in breast cancer patients. ABC family members (http://www.gene.ucl.ac.uk/nomenclature/genefamily/ abc.html and http://www.med.rug.nl/mdl/humanabc. htm) [13] [14] [15] involved in MDR include multiple drug resistance 1/P-glycoprotein (MDR1/Pgp) (ABCB1), multidrug resistance-associated protein (MRP) family members MRP1 (ABCC1), MRP2 (ABCC2), MRP3 (ABCC3), MRP4 (ABCC4), MRP5 (ABCC5), MRP6 (ABCC6), and breast cancer resistance protein (BCRP) (ABCG2).
MDR1/Pgp Expression
The MDR1 gene encodes Pgp, a 170-kDa protein consisting of 12 transmembrane domains and two ATP-binding domains [16, 17] . Drugs to which MDR1/Pgp confers resistance include anthracyclines [18] , epipodophyllotoxins, vinca alkaloids, geldanamycin [15] and taxanes [19] ; apparently, methotrexate, 5-fl uorouracil, camptothecins and hydroxyurea are not substrates for MDR1/Pgp [15] .
The relevance of MDR1/Pgp gene expression in breast cancer has been extensively investigated, with contradictory results ranging from 0 to 100% expression in tumour cells [8, 18] and with confl icting reports as to its prognostic/predictive relevance. A meta-analysis of such studies reported MDR1/Pgp protein to be expressed in approximately 41% of breast tumours and associated with poor response to treatment [20] . Similarly, in a study specifically of chemotherapy-naïve breast tumours, MDR1/Pgp protein expression (found in 37% of cases) was reported to be signifi cantly associated with shortened disease-free survival (DFS), when compared with those that were MDR1/Pgp negative [21] . In contrast, overexpression of MDR1/Pgp protein in locally advanced breast cancer following neoadjuvant chemotherapy -cyclophosphamide + doxorubicin + 5-fl uorouracil, taxotere + doxorubicin, or cyclophosphamide + methotrexate + 5-fl uorouracil (CMF) -showed no correlation with response to chemotherapy [22] . Similarly, our study of 177 invasive breast carcinomas showed no association between MDR1/Pgp protein expression at diagnosis and patients' outcome [23] . Of course, such studies can assess only protein levels, not activity.
MRP1 Expression
The MRP subfamily is comprised of nine members that transport structurally diverse lipophilic anions and hydrophilic peptides [24] . MRP1 gene encodes a 190-kDa transmembrane protein associated with both cell membrane and intracellular membrane expression [12] . MRP1 confers resistance to anthracyclines, epipodophyllotoxins, methotrexate, and the vinca alkaloid vincristine; however, it apparently confers no/only low-level resistance to vinblastine [25] . In contrast to MDR1/Pgp, taxanes are poor substrates for MRP1 and its overexpression in cell lines has been shown not to confer resistance to cisplatin and mitoxanthrone [26] .
In general, there appears to be a correlation between MRP1 protein expression and poor outcome for breast cancer patients, although a direct causal role for MRP1 in clinical drug resistance remains to be determined [12] . In a study of 100 primary breast cancer tumours, the absence of MRP1 protein was found to be signifi cantly associated with increased DFS and overall survival (OS), compared with those with MRP1 tumours [27] . In our study of 177 invasive breast carcinomas, we found no association between MRP1 expression at diagnosis (presence/absence and ! 25% MRP1 expression versus 6 25% MRP1 expression) and either DFS or OS. However, a signifi cant correlation was observed between MRP1 protein expression in 6 25% tumour cells and shorter DFS or OS for patients with high-grade tumours (grade III) who received adjuvant CMF. Multivariate analysis iden-tifi ed MRP1 expression in this subgroup to be an independent poor prognostic factor for both DFS and OS [23] . Furthermore, the relevance of MRP1 in patients treated with CMF has more recently been confi rmed in a study of 516 premenopausal, hormone receptor-positive breast cancer patients with stage I and II disease, where MRP1 expression was found to be an independent predictor of shorter relapse-free survival and OS [28] .
Studies investigating the relevance in breast cancer MDR of more recently described members of the MRP family, such as MRP2 [29] and MRP8 [30] , have commenced. An analysis of MRP1, MRP2 and MRP3 mRNA expression in untreated and post-neoadjuvant anthracycline-based tumours indicated expression of all three family members in 100% specimens studied, with no signifi cant increase in levels after chemotherapy. Corresponding proteins, however, were not detectable [31] . MRP7 may confer resistance to taxanes [32] . More extensive studies are now necessary to investigate the clinical relevance (in any) to breast cancer of expression of all MRP family members.
Role of BCRP BCRP (also known as mitoxanthrone resistance gene) is a 72-kDa half-transporter consisting of six transmembrane domains with one ATP-binding domain [33] . BCRP transports a number of anticancer drugs including mitoxanthrone, methotrexate, topotecan, irinotecan, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, fl avopiridol, and quinazoline ErbB1 inhibitors, and its transportation of anthracyclines depends on a mutation at codon 482 [12, 34, 35] . However, although described as 'breast cancer resistance protein', the defi nitive role of BCRP in clinical drug resistance in breast cancer is still unclear [36] .
Lung Resistance Protein
Lung resistance protein (LRP; also known as major vault protein), a 110-kDa protein, is not an ABC transporter, but its expression is frequently detected at high levels in drug-resistant cell lines and tumour specimens. Expression of LRP has been associated with resistance to platinum, alkylating agents [37] and doxorubicin [38] . An immunohistochemistry study of LRP in 99 primary breast carcinomas indicated low-level expression in 20%, intermediate-level expression in 47%, and high-level expression in 21% of cases (LRP was undetected in 12% of these breast carcinomas). However, expression was not signifi cantly associated with clinicopathological characteristics evaluated, including patients' DFS or OS [39] .
Similarly, a study of 80 locally advanced breast carcinomas showed no correlation between LRP protein expression and clinical parameters evaluated [40] .
Other Mechanisms of MDR in Breast Cancer
In addition to drug effl ux pumps that may contribute to MDR by reduction in the intracellular accumulation of anticancer drugs (as a result of both increasing drug effl ux and/or decreasing drug uptake and drug sequestration in subcellular organelles), other mechanisms of drug resistance have been described in breast cancer. These include alterations in drug targets -e.g., topoisomerase enzymes [41] [42] [43] and activation of detoxifying systems including glutathione/glutathione S-transferases [44] [45] [46] and cytochrome P450 enzymes [47, 48] -increased repair of drug-induced DNA damage, disruption in cell signalling, alterations in factors involved in cell cycle control, and inhibition of apoptosis [12] . Due to space limitations, an extensive review of these MDR mechanisms is beyond the scope of this manuscript.
Future Prospects
Recent studies involving the application of expression microarrays, including the work of van't Veer et al. [49] identifying 70 discriminatory genes between metastatic and non-metastatic breast carcinomas and studies reported by Wang et al. [50] identifying a 76 gene signature relevant to distant metastasis of lymph node-negative primary breast tumours, indicate the importance and relevance of such molecular profi ling analyses. More extensive microarray and proteomics profi ling of larger and different cohorts of breast clinical specimens should facilitate the future development of rational combination chemotherapy regimes, in which cytotoxic drugs may be administered with newer targeted therapies, as relevant, to individuals or particular subgroups of breast cancer patients.
